Saturday 17 October 2026
Export HUM’s income statement to Excel — free account
Humana Inc.
HUM Healthcare Healthcare Plans
Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 26.2%, EPS grew 27.9%, free cash flow grew 58.5% and total debt rose 13.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.
413.16
19.04
−4.41%
Follow HUM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
37.30 | 18.47 | 26.03 | 24.34 |
+8 more quarters Free account |
P/S ratio |
0.33 | 0.15 | 0.24 | 0.25 | |
P/FCF ratio |
24.18 | 16.11 | 77.52 | 20.14 | |
P/Operating CF |
24.26 | 16.64 | (18.68) | 32.23 | |
P/B ratio |
2.47 | 1.12 | 1.74 | 1.68 | |
Price to Tangible BV |
5.42 | 2.56 | 3.83 | 3.49 | |
EV/Sales |
0.26 | 0.09 | 0.18 | 0.18 | |
EV/EBITDA |
10.92 | 3.97 | 6.77 | 5.82 | |
EV/Operating CF |
14.99 | 6.99 | 25.94 | 10.93 | |
EV/FCF |
19.30 | 9.96 | 60.04 | 14.38 | |
Quick Ratio |
1.29 | 1.26 | 1.42 | 1.53 | |
Current Ratio |
1.74 | 1.77 | 2.00 | 2.02 | |
Net Debt/EBITDA |
(6.22) | (4.09) | 12.27 | (15.76) | |
Debt/Assets |
24.91% | 25.31% | 25.29% | 25.36% | |
Debt/Equity |
0.74 | 0.75 | 0.70 | 0.68 | |
Asset Turnover |
2.71 | 2.58 | 2.72 | 2.53 | |
Operating CF/Net income |
2.83 | 1.06 | 2.08 | 4.98 | |
Capex/Depreciation |
(0.70) | (0.62) | (0.92) | (0.66) | |
Interest Coverage |
6.90 | 9.09 | (5.53) | 2.38 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.18 | 0.19 | 0.20 | 0.19 | |
Share Based Compensation of Revenue |
0.16% | 0.13% | 0.15% | 0.25% | |
Graham Net Nets |
0.05 | 0.07 | 0.05 | 0.05 | |
Graham Number |
196.14 | 180.94 | 180.56 | 192.77 | |
Earnings Yield |
2.68% | 5.42% | 3.84% | 4.11% | |
Free Cash Flow Yield |
4.13% | 6.21% | 1.29% | 4.97% | |
Revenue per Share |
340.37 | 329.49 | 269.94 | 271.46 | |
Operating CF per Share |
16.37 | 10.42 | (13.71) | 8.07 | |
Capex per Share |
(1.10) | (1.01) | (1.49) | (1.12) | |
Free Cash Flow per Share |
15.27 | 9.42 | (15.20) | 6.95 | |
Cash per Share |
198.82 | 182.54 | 165.23 | 183.95 | |
Shareholders Equity per Share |
160.55 | 154.95 | 147.25 | 154.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
160.55 | 154.95 | 147.25 | 154.50 | |
Free Cash Flow |
1,834.00 | 1,133.00 | (1,831.00) | 836.00 | |
Working Capital |
17,079.00 | 16,573.00 | 16,387.00 | 16,572.00 | |
Capital Expenditures |
(132.00) | (121.00) | (179.00) | (135.00) | |
Net Current Asset Value |
2,167.00 | 1,446.00 | 1,561.00 | 1,615.00 | |
EV/EBIT |
14.07 | 5.28 | 8.84 | 7.53 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
17.62 | 8.54 | 11.41 | 10.54 | |
| Other line items | |||||
Average Receivables |
5,099.50 | 4,838.50 | 2,987.00 | 2,414.00 | |
Average Payables |
6,425.00 | 5,955.50 | 5,488.00 | 5,717.00 | |
Average Assets |
53,776.50 | 53,105.00 | 47,694.00 | 49,863.00 | |
Average Common Equity |
18,786.00 | 18,232.50 | 17,091.00 | 18,103.00 |
Columns are period end dates